<DOC>
	<DOCNO>NCT02077465</DOCNO>
	<brief_summary>This study ass safety , tolerability , pharmacokinetics ( PK ) multiple infusion GS-5745 participant chronic obstructive pulmonary disease ( COPD ) assess adverse event ( AEs ) laboratory abnormality .</brief_summary>
	<brief_title>Safety , Tolerability , Pharmacokinetics GS-5745 Subjects With Chronic Obstructive Pulmonary Disease ( COPD )</brief_title>
	<detailed_description />
	<mesh_term>Lung Diseases</mesh_term>
	<mesh_term>Lung Diseases , Obstructive</mesh_term>
	<mesh_term>Pulmonary Disease , Chronic Obstructive</mesh_term>
	<criteria>Weight : ≥ 45 kg &lt; 120 kg screen Males nonpregnant , nonlactating female Male subject female subject childbearing potential engage heterosexual intercourse must agree use protocol specify method ( ) contraception . Male subject must refrain sperm donation 90 day post last infusion study drug Diagnosis COPD per Global Initiative Chronic Obstructive Lung Disease ( GOLD ) guideline least 6 month prior screen anticipate remain stable therapy duration study Postbronchodilator force expiratory volume one second ( FEV1 ) ≥ 40 % predict No change COPD medication within 30 day prior randomization Hepatic panel [ aspartate aminotransferase ( AST ) , alanine aminotransferase ( ALT ) , total bilirubin , direct bilirubin , alkaline phosphatase , lactate dehydrogenase ( LDH ) ] ≤ 2 time upper limit normal range ( ULN ) Serum creatinine ≤ 2.0 Hemoglobin ≥ 8.5 g/dL ( male female ) Absolute neutrophil count ( ANC ) ≥ 1.5 x 10^9/L ( 1,500 mm^3 ) Platelets ≥ 100 x 10^9/L Clinically significant active infection judge investigator screen Known history HIV , hepatitis B C screening . Subjects hepatitis B surface antigen positive , receive successful series hepatitis B vaccination never disease remain eligible A positive QuantiFERONTB GOLD test screen History malignancy within last 5 year except patient treat locally nonmelanoma skin cancer cervical carcinoma situ Any serious cardiac event myocardial infarction , unstable lifethreatening arrhythmia , hospitalization cardiac failure within 6 month prior randomization significant new electrocardiogram ( ECG ) find Visit 1 judge Investigator A hospitalization respiratory event , limited , COPD , pneumonia , bronchiolitis , within previous 6 month prior randomization Chronic lung disease COPD : asthma , cystic fibrosis fibrotic disease , α1antitrypsin deficiency , interstitial lung disease , pulmonary thromboembolic disease , bronchiectasis Chronic use systemic corticosteroid and/or treatment systemic corticosteroid acute exacerbation COPD ( AECOPD ) event , medical condition require hospitalization , within 90 day randomization . Treatment antibiotic AECOPD event , medical condition require hospitalization within 90 day randomization , minor medical event require hospitalization within 14 day randomization . Treatment market investigational biologic within 5 halflives molecule unknown within 90 day screen Subjects currently nonbiologic immune modulator medication : azathioprine , cyclosporine , hydroxychloroquine , leflunomide , methotrexate , mycophenolate mofetil , sulfasalazine , tofacitinib , within 90 day randomization</criteria>
	<gender>All</gender>
	<minimum_age>40 Years</minimum_age>
	<maximum_age>75 Years</maximum_age>
	<verification_date>February 2015</verification_date>
	<keyword>COPD , chronic obstructive pulmonary disease ; Phase 1b , Safety , Pharmacokinetics</keyword>
</DOC>